Amirhossein Sahebkar

Amirhossein Sahebkar is an Iranian biotechnologist specializing in cardiovascular diseases. He is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences.

Life

Sahebkar completed a Pharm.D. in 2008 from Mashhad University of Medical Sciences. His dissertation was titled, An investigation of serum antibody titres to heat shock protein 27 (anti- Hsp27) as a biomarker for the detection of acute coronary syndrome. Sahebkar earned a Ph.D. in pharmaceutical biotechnology from the Mashhad University of Medical Sciences. His dissertation was titled, Preparation and evaluation of nanoliposomes conjugated with apolipoprotein B-100 antibodies as a therapeutic option for serum LDL reduction. He completed a postdoctoral fellowship in cardiometabolic diseases at the University of Western Australia.

Sahebkar is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences. His research focuses on cardiovascular disease, atherosclerosis, and blood lipids. He is a member of the Iran's National Elites Foundation. In 2016, he was presented the Professor Dr. Fereydoun Azizi award by the Iranian Academy of Medical Sciences.

Retractions

As of August 24, 2024, 7 scientific articles co-authored by Sahebkar have been retracted.

1. Mirzaei, Hamed, et al. "The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model." Cancer letters 419 (2018): 39-30. - "[T]here are multiple identical details between Fig. 5A (Cancer Letters) and Fig. 3A (Stem Cells) and the authors did not produce satisfactory evidence that the published images in Cancer Letters were original."
2. Momtazi-Borojeni, Amir Abbas, et al. "Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis." BMC medicine 17 (2019): 1-15. - "The left PHA image in Fig. 7a appears highly similar to the middle PHA image in Fig. 7b (rotated); All the Medium images in Fig. 7a and b appear highly similar; the left and right images in Fig. 7b appear to be missing some features compared with the other images."
3. Aalami, Amir Hossein, et al. "[Retracted] Urinary Angiogenin as a Marker for Bladder Cancer: A Meta‐Analysis." BioMed Research International 2021.1 (2021): 5557309. - "[I]nvestigation has uncovered evidence of systematic manipulation of the publication and peer-review process."
4. Korani, Shahla, et al. "[Retracted] Evaluation of Antimicrobial and Wound Healing Effects of Gold Nanoparticles Containing Abelmoschus esculentus (L.) Aqueous Extract." Bioinorganic chemistry and applications 2021.1 (2021): 7019130. - "[I]nvestigation has uncovered evidence of systematic manipulation of the publication and peer-review process."
5. Ganjali, Shiva, et al. "[Retracted] Association between Oxidative Burden and Restenosis: A Case‐Control Study." Oxidative Medicine and Cellular Longevity 2022.1 (2022): 3577761. - "[I]nvestigation has uncovered evidence of systematic manipulation of the publication and peer-review process."
6. Jamialahmadi, Tannaz, et al. "[Retracted] The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta‐Analysis." Oxidative medicine and cellular longevity 2022.1 (2022): 7850659. - [I]nvestigation has uncovered evidence of systematic manipulation of the publication and peer-review process."
7. Stamerra, Cosimo Andrea, et al. "[Retracted] Mitochondrial Dysfunction and Cardiovascular Disease: Pathophysiology and Emerging Therapies." Oxidative Medicine and Cellular Longevity 2022.1 (2022): 9530007. - [I]nvestigation has uncovered evidence of systematic manipulation of the publication and peer-review process."

Note that articles 3 - 7 were retracted following the same investigation. Overall, the investigation led to over 7000 article retractions in Hindawi journals related to the publication of articles originating from paper mills.